MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ
2.190
+0.220
+11.17%
After Hours: 2.180 -0.01 -0.46% 19:06 02/06 EST
OPEN
1.980
PREV CLOSE
1.970
HIGH
2.195
LOW
1.980
VOLUME
738.12K
TURNOVER
--
52 WEEK HIGH
4.965
52 WEEK LOW
1.350
MARKET CAP
164.33M
P/E (TTM)
-22.0322
1D
5D
1M
3M
1Y
5Y
1D
Eledon Pharmaceuticals to Join Guggenheim Emerging Outlook Biotech Summit
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), High Tide (HITI) and Lonza Group (OtherLZAGY)
TipRanks · 5d ago
Weekly Report: what happened at ELDN last week (0126-0130)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/29 21:05
Eledon Pharmaceuticals: Sustained Tegoprubart Efficacy, Differentiated Safety, and Upcoming Transplant Catalysts Support Buy Rating
TipRanks · 01/26 12:56
Weekly Report: what happened at ELDN last week (0119-0123)?
Weekly Report · 01/26 10:27
Eledon Pharmaceuticals Reports Positive 24-Month Phase 1b Data for Tegoprubart in Kidney Transplant Patients
Reuters · 01/26 06:51
Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)
TipRanks · 01/23 14:50
More
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Webull offers Eledon Pharmaceuticals Inc stock information, including NASDAQ: ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.